FDA grants Priority Review to BeOne Medicines' BRUKINSA combination in first-line mantle cell lymphoma

BeOne Medicines announced the U.S. FDA granted Priority Review to its supplemental New Drug Application for BRUKINSA (zanubrutinib) in combination with rituximab for adult patients with previously untreated mantle cell lymphoma, supported by Phase 3 MANGROVE data.

Detected & updated continuously · Source: Nebula